Targeting autophagy potentiates the apoptotic effect of histone deacetylase inhibitors in t(8;21) AML cells

Blood

Volumn 122, Issue 14, 2013, Pages 2467-2476

  Torgersen, Maria Lyngaas ^a   Engedal, Nikolai ^b   Bøe, Stig Ove ^c   Hokland, Peter ^d   Simonsen, Anne ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AML1 EIGHT TWENTY ONE FUSION PROTEIN; CASPASE 3; CELL MARKER; CHLOROQUINE; HYBRID PROTEIN; LC3II PROTEIN; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; ONCOPROTEIN; ORIDONIN; PHOSPHATIDYLETHANOLAMINE; TRANSCRIPTION FACTOR RUNX1; UBIQUITINATED PROTEIN; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT; AML1 ETO FUSION PROTEIN, HUMAN; AML1-ETO FUSION PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID;

ACUTE MYELOID LEUKEMIA; ACUTE MYELOID LEUKEMIA CELL LINE; APOPTOSIS; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; CELL DEATH; CELL FUNCTION; CELL VIABILITY; COLONY FORMING UNIT; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME INHIBITION; GENE EXPRESSION; HL-60 CELL LINE; HUMAN; HUMAN CELL; LEUKEMOGENESIS; LONG TERM CARE; LONG TERM EXPOSURE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; TARGET CELL; UBIQUITINATION; ACUTE GRANULOCYTIC LEUKEMIA; CHROMOSOME 8; DRUG EFFECT; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENETIC TRANSFECTION; IMMUNOBLOTTING; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; AUTOPHAGY; CELL LINE, TUMOR; CHLOROQUINE; CHROMOSOMES, HUMAN, PAIR 8; CORE BINDING FACTOR ALPHA 2 SUBUNIT; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; IMMUNOBLOTTING; LEUKEMIA, MYELOID, ACUTE; ONCOGENE PROTEINS, FUSION; TRANSFECTION; VALPROIC ACID;

EID: 84887740107     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-05-500629     Document Type: Article

References (47)

1. Yang Z, Klionsky DJ. Mammalian autophagy: core molecular machinery and signaling regulation. Curr Opin Cell Biol. 2010;22(2): 124-131.
2. Levy JM, Thorburn A. Targeting autophagy during cancer therapy to improve clinical outcomes. Pharmacol Ther. 2011;131(1):130-141.
3. White E. Deconvoluting the context-dependent role for autophagy in cancer. Nat Rev Cancer. 2012;12(6):401-410.
4. Chen S, Rehman SK, Zhang W, Wen A, Yao L, Zhang J. Autophagy is a therapeutic target in anticancer drug resistance. Biochim Biophys Acta. 2010;1806(2):220-229.
5. Amaravadi RK, Lippincott-Schwartz J, Yin XM, et al. Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res. 2011;17(4):654-666.
6. Shen S, Kepp O, Kroemer G. The end of autophagic cell death? Autophagy. 2012; 8(1):1-3.
7. Isakson P, Bjørås M, Bøe SO, Simonsen A. Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein. Blood. 2010;116(13):2324-2331.
8. Wang Z, Cao L, Kang R, et al. Autophagy regulates myeloid cell differentiation by p62/SQSTM1-mediated degradation of PML-RARα oncoprotein. Autophagy. 2011;7(4):401-411.
9. Goussetis DJ, Gounaris E, Wu EJ, et al. Autophagic degradation of the BCR-ABL oncoprotein and generation of antileukemic responses by arsenic trioxide. Blood. 2012; 120(17):3555-3562.
10. Elzinga BM, Nyhan MJ, Crowley LC, O'Donovan TR, Cahill MR, McKenna SL. Induction of autophagy by Imatinib sequesters Bcr-Abl in autophagosomes and down-regulates Bcr-Abl protein. Am J Hematol. 2013;88(6):455-462.
11. Reikvam H, Hatfield KJ, Kittang AO, Hovland R, Bruserud O. Acute myeloid leukemia with the t(8;21) translocation: clinical consequences and biological implications. J Biomed Biotechnol. 2011;2011:104631.
12. Ververis K, Hiong A, Karagiannis TC, Licciardi PV. Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents. Biologics. 2013; 7:47-60.
13. Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs. 2002;16(10): 695-714.
14. Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol. 2007;25(1):84-90.
15. Wang J, Saunthararajah Y, Redner RL, Liu JM. Inhibitors of histone deacetylase relieve ETOmediated repression and induce differentiation of AML1-ETO leukemia cells. Cancer Res. 1999; 59(12):2766-2769.
16. Liu S, Klisovic RB, Vukosavljevic T, et al. Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells. J Pharmacol Exp Ther. 2007;321(3):953-960.
17. Tabe Y, Jin L, Contractor R, et al. Novel role of HDAC inhibitors in AML1/ETO AML cells: activation of apoptosis and phagocytosis through induction of annexin A1. Cell Death Differ. 2007; 14(8):1443-1456.
18. Krämer OH, Müller S, Buchwald M, Reichardt S, Heinzel T. Mechanism for ubiquitylation of the leukemia fusion proteins AML1-ETO and PMLRARalpha. FASEB J. 2008;22(5):1369-1379.
19. Zapotocky M, Mejstrikova E, Smetana K, Stary J, Trka J, Starkova J. Valproic acid triggers differentiation and apoptosis in AML1/ETOpositive leukemic cells specifically. Cancer Lett. 2012;319(2):144-153.
20. Barbetti V, Gozzini A, Cheloni G, et al. Time- and residue-specific differences in histone acetylation induced by VPA and SAHA in AML1/ETO-positive leukemia cells. Epigenetics. 2013;8(2):210-219.
21. Carew JS, Nawrocki ST, Kahue CN, et al. Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. Blood. 2007;110(1):313-322.
22. Li J, Liu R, Lei Y, et al. Proteomic analysis revealed association of aberrant ROS signaling with suberoylanilide hydroxamic acid-induced autophagy in Jurkat T-leukemia cells. Autophagy. 2010;6(6):711-724.
23. Carew JS, Medina EC, Esquivel JA II, et al. Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation. J Cell Mol Med. 2010;14(10):2448-2459.
24. Liu YL, Yang PM, Shun CT, Wu MS, Weng JR, Chen CC. Autophagy potentiates the anti-cancer effects of the histone deacetylase inhibitors in hepatocellular carcinoma. Autophagy. 2010;6(8): 1057-1065.
25. Lopez G, Torres K, Liu J, et al. Autophagic survival in resistance to histone deacetylase inhibitors: novel strategies to treat malignant peripheral nerve sheath tumors. Cancer Res. 2011;71(1):185-196.
26. Thomas S, Thurn KT, Biçaku E, Marchion DC, Münster PN. Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy. Breast Cancer Res Treat. 2011;130(2):437-447.
27. Gammoh N, Lam D, Puente C, Ganley I, Marks PA, Jiang X. Role of autophagy in histone deacetylase inhibitor-induced apoptotic and nonapoptotic cell death. Proc Natl Acad Sci USA. 2012;109(17):6561-6565.
28. Zhou GB, Kang H, Wang L, et al. Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivo. Blood. 2007;109(8):3441-3450.
29. Zhen T, Wu CF, Liu P, et al. Targeting of AML1-ETO in t(8;21) leukemia by oridonin generates a tumor suppressor-like protein. Sci Transl Med. 2012;4(127):127ra138.
30. Mizushima N, Yoshimori T, Levine B. Methods in mammalian autophagy research. Cell. 2010; 140(3):313-326.
31. Lu Y, Peng ZG, Yuan TT, Yin QQ, Xia L, Chen GQ. Multi-sites cleavage of leukemogenic AML1-ETO fusion protein by caspase-3 and its contribution to increased apoptotic sensitivity. Leukemia. 2008;22(2):378-386.
32. Fang HT, Zhang B, Pan XF, et al. Bortezomib interferes with C-KIT processing and transforms the t(8;21)-generated fusion proteins into tumorsuppressing fragments in leukemia cells. Proc Natl Acad Sci USA. 2012;109(7):2521-2526.
33. Szumiel I. Autophagy, reactive oxygen species and the fate of mammalian cells. Free Radic Res. 2011;45(3):253-265.
34. Malhotra JD, Kaufman RJ. Endoplasmic reticulum stress and oxidative stress: a vicious cycle or a double-edged sword? Antioxid Redox Signal. 2007;9(12):2277-2293.
35. Sztajnkrycer MD. Valproic acid toxicity: overview and management. J Toxicol Clin Toxicol. 2002; 40(6):789-801.
36. New M, Olzscha H, La Thangue NB. HDAC inhibitor-based therapies: can we interpret the code? Mol Oncol. 2012;6(6):637-656.
37. Cai D, Wang Y, Ottmann OG, Barth PJ, Neubauer A, Burchert A. FLT3-ITD-, but not BCR/ABLtransformed cells require concurrent Akt/mTor blockage to undergo apoptosis after histone deacetylase inhibitor treatment. Blood. 2006; 107(5):2094-2097.
38. Graef M, Nunnari J. Mitochondria regulate autophagy by conserved signalling pathways. EMBO J. 2011;30(11):2101-2114.
39. Dickinson M, Johnstone RW, Prince HM. Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect. Invest New Drugs. 2010;28(Suppl 1):S3-S20.
40. Park S, Chapuis N, Tamburini J, et al. Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia. Haematologica. 2010;95(5): 819-828.
41. Wang YY, Zhou GB, Yin T, et al. AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec. Proc Natl Acad Sci USA. 2005;102(4):1104-1109.
42. Riera L, Marmont F, Toppino D, et al. Core binding factor acute myeloid leukaemia and c-KIT mutations. Oncol Rep. 2013;29(5):1867-1872.
43. Lum JJ, Bauer DE, Kong M, et al. Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell. 2005;120(2):237-248.
44. Petruccelli LA, Pettersson F, Del Rincón SV, Guilbert C, Licht JD, Miller WH Jr. Expression of leukemia-associated fusion proteins increases sensitivity to histone deacetylase inhibitorinduced DNA damage and apoptosis. Mol Cancer Ther. 2013;12(8):1591-1604.
45. Martens JH, Stunnenberg HG. The molecular signature of oncofusion proteins in acute myeloid leukemia. FEBS Lett. 2010;584(12):2662-2669.
46. Romanski A, Schwarz K, Keller M, et al. Deacetylase inhibitors modulate proliferation and self-renewal properties of leukemic stem and progenitor cells. Cell Cycle. 2012;11(17): 3219-3226.
47. Ptasinska A, Assi SA, Mannari D, et al. Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding. Leukemia. 2012; 26(8):1829-1841.